Chronic Lymphocytic Leukemia News

Chronic Lymphocytic Leukemia News

Underdosing in Patients With Cancer and Obesity: A Thing of the Past?

Publish Date June 16, 2021

New guidelines recommend using the full approved doses of immunotherapy and targeted therapies for patients with cancer and obesity.

CLL/SLL: Ibrutinib, Venetoclax Therapy May Improve Outcomes in First Line

Publish Date June 13, 2021

The tumor lysis syndrome risk decreased for 84.6% of patients in the ibrutinib/venetoclax group.

Impaired Immune Response to COVID-19 Vaccine Observed in Patients With Chronic Lymphocytic Leukemia

Publish Date June 3, 2021

Patients with chronic lymphocytic leukemia had a significantly reduced antibody response rate when compared with healthy individuals.

Age and Race May Determine Whether Cancer Patients Access Their Electronic Health Records

Publish Date June 2, 2021

Black cancer patients were 44% less likely than White patients to enroll in a portal that provides access to electronic health records.

GAB1 Inhibitors Show Promise as Treatment Option for Chronic Lymphocytic Leukemia

Publish Date June 2, 2021

GAB1 inhibitors impaired migration of chronic lymphocytic leukemia cells and induced apoptosis.

MEK Inhibitors May Overcome Resistance to PI3K Inhibitors in Chronic Lymphocytic Leukemia

Publish Date May 28, 2021

Activation of the MAPK/ERK pathway mediates resistance to PI3K inhibitors, researchers found.

Acalabrutinib May Be a Therapeutic Option in Treatment-Naive Chronic Lymphocytic Leukemia

Publish Date May 7, 2021

Researchers sought to determine the recommended dose, safety, efficacy, pharmacokinetics, and pharmacodynamics of acalabrutinib in patients with symptomatic untreated CLL.

Phase 3 Trial Compares LOXO-305 to Investigator’s Choice in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Publish Date April 23, 2021

The primary outcome measure of the trial is to evaluate progression-free survival after LOXO-305 monotherapy compared to investigator’s choice.

Clinical Trial: Zanubrutinib Plus Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia

Publish Date April 23, 2021

The researchers hypothesize that zanubrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Certain Mutations May Be Associated With Infection Risk for Patients With Chronic Lymphocytic Leukemia

Publish Date April 21, 2021

Researchers sought to determine factors that may impact infection risk in patients with CLL.

Upfront Low-Dose Chemo-Immunotherapy Safe, Effective for Elderly With CLL

Publish Date April 7, 2021

A study was conducted to assess the safety and efficacy of fludarabine and cyclophosphamide combined with rituximab for the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma in elderly patients and those with comorbid conditions.

Anti-CD20 Antibody Improved Response to Ibrutinib in High-Risk R/R CLL

Publish Date April 1, 2021

Investigators conducted a randomized controlled trial to determine whether the addition of ublituximab to treatment with ibrutinib improved outcomes in patients with relapsed or refractory chronic lymphocytic leukemia.

Lenalidomide Maintenance Therapy Linked With B-Cell Acute Lymphoblastic Leukemia in Patients With Chronic Lymphocytic Leukemia

Publish Date March 26, 2021

Researchers sought to describe a potential link between treatment with lenalidomide and development of B-cell ALL in patients with CLL.

BTK Inhibitors for CLL Lower Response to Some Vaccines

Publish Date March 24, 2021

A team of investigators conducted a phase 2 trial to assess outcomes of hepatitis C virus and varicella zoster vaccination in patients with treatment-naive CLL or those on BTK inhibitor therapy.

Safety Profile of Obinutuzumab for CLL Confirmed in Final Analysis of GREEN Study

Publish Date March 19, 2021

The open-label, nonrandomized phase 3b GREEN trial assessed the safety of obinutuzumab monotherapy or obinutuzumab plus chlorambucil, bendamustine, or fludarabine and cyclophosphamide in patients with chronic lymphocytic leukemia.

Prognostic Biomarker Testing in CLL/SLL Remains Low

Publish Date December 11, 2020

Clinicians are not following guideline recommendations, as prognostic biomarker testing for CLL/SLL remains low and affects treatment selection.

Clinical Trial: Investigational BTK Inhibitor Undergoes Investigation in CLL, B-Cell Lymphoma

Publish Date February 19, 2021

Investigators will study the pharmacokinetic and pharmacodynamic profile of TG-1701, an irreversible Bruton tyrosine kinase (BTK) inhibitor, in the phase 1 setting.

Data From the CAPTIVATE Study’s uMRD Cohort Suggest Role for Fixed-Duration Therapy in CLL/SLL [Q&A]

Publish Date February 9, 2021

John N. Allan, MD, a lead author of the CAPTIVATE study, discusses the findings from the uMRD cohort and their implications for the CLL/SLL paradigm.

American Cancer Society 2021 Statistics Report Shows Continuous Decline in Cancer Mortality Rate, Illuminates Disease-Specific Trends

Publish Date February 4, 2021

The American Cancer Society’s annual report approximates the new cancer diagnoses and deaths expected in 2021 and identifies impactful patterns in oncology care.

Idelalisib Does not Increase Risk for Bleeding in Patients With CLL, Indolent NHL Receiving Anticoagulation/Antiplatelet Therapy

Publish Date January 12, 2021

This post-hoc analysis assessed the incidence and characteristics of bleeding-related adverse events in patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma enrolled in the idelalisib registration trials.